论文部分内容阅读
目的探讨香菇多糖注射液联合伊立替康治疗晚期结直肠癌的临床疗效。方法选取2015年9月—2016年9月在南方医科大学南方医院接受治疗的晚期结直肠癌患者74例,随机分为对照组(37例)和治疗组(37例)。对照组静脉滴注盐酸伊立替康注射液,180 mg/m2加入250 m L生理盐水中,1次/3周。治疗组在对照组的基础上静脉滴注香菇多糖注射液,2 m L加入5%葡萄糖溶液250 m L中,1次/d。两组患者均连续治疗6周。治疗后,比较两组患者临床效果、生存质量改善情况和血清学指标。结果治疗后,对照组与治疗组的客观缓解率(ORR)分别为48.65%、70.27%,临床获益率(CBR)分别为70.27%、91.89%,两组比较差异有统计学意义(P<0.05)。治疗后,对照组生存质量总改善率为72.97%,显著低于治疗组的94.59%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者基质金属蛋白酶-2(MMP-2)水平均下降,而白细胞介素-2(IL-2)和干扰素-γ(IFN-γ)水平均升高,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组患者的上述观察指标改善情况显著优于对照组患者,两组比较差异具有统计学意义(P<0.05)。结论香菇多糖注射液联合伊立替康治疗晚期结直肠癌具有较好的临床疗效,可明显提高机体免疫能力和改善生活质量,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of lentinan combined with irinotecan in the treatment of advanced colorectal cancer. Methods Seventy-four patients with advanced colorectal cancer who were treated in Nanfang Hospital of Southern Medical University from September 2015 to September 2016 were randomly divided into control group (37 cases) and treatment group (37 cases). The control group was given IV irinotecan hydrochloride intravenous injection, 180 mg / m2 was added to 250 m L normal saline, once / 3 weeks. The treatment group was given intravenous infusion of lentinan injection on the basis of the control group, 2 mL of 250 mL of 5% dextrose solution, once / d. Two groups of patients were treated for 6 weeks. After treatment, the clinical effects, quality of life improvement and serological indicators were compared between the two groups. Results After treatment, the objective response rates (ORR) of the control group and the treatment group were 48.65% and 70.27%, respectively, and the clinical benefit rates (CBR) were 70.27% and 91.89% respectively, with significant difference between the two groups (P < 0.05). After treatment, the total quality of life in the control group was 72.97%, significantly lower than 94.59% in the treatment group. There was significant difference between the two groups (P <0.05). After treatment, the levels of MMP-2 decreased and the levels of IL-2 and IFN-γ increased in both groups before and after treatment (P <0.05). The improvement of the above observation indexes in the treatment group was significantly better than that in the control group, the difference between the two groups was statistically significant (P <0.05). Conclusion Lentinan injection combined with irinotecan in the treatment of advanced colorectal cancer has a good clinical efficacy, can significantly improve the immune capacity and improve the quality of life, with some clinical application value.